Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Rhea-AI Summary

Aprea Therapeutics (APRE) will present updated interim Phase 1 data from the ongoing ACESOT-1051 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, taking place November 18-20, 2026.

The presentation, titled “Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)”, is scheduled for Friday, November 20, 2026, from 3:00 PM to 3:10 PM CET in Room 111 + 112 at the CCIB. The presenting author will be Timothy A. Yap, MBBS, PhD, FRCP, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and an investigator in the ACESOT-1051 study. Additional information on ACESOT-1051 is available under identifier NCT06260514 on ClinicalTrials.gov.

Key Figures

Presentation date: November 20, 2026

Presentation date

November 20, 2026

Oral presentation of updated interim Phase 1 results

Key Terms

wee1 inhibitor, first-in-human

2 terms

wee1 inhibitor technical

"updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051"

A Wee1 inhibitor is a drug that blocks the Wee1 protein, which normally acts like a safety brake that pauses damaged cells before they divide. By removing that brake, cancer cells with DNA damage are forced into division and often die, making the approach useful for targeting tumors. Investors track Wee1 inhibitors because their clinical trial success, safety profile and use with other therapies can greatly affect a biotechnology company's value.

first-in-human medical

"Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that an abstract featuring updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to take place November 18-20, 2026, in Barcelona, Spain.

“We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Symposium and sharing these data with the international oncology community,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “This meeting brings together leading investigators, clinicians and researchers focused on advancing new approaches in cancer treatment, and we welcome the opportunity to discuss our program with the broader oncology community in Barcelona.”

Presentation Details:

Title:	Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)
Presenting Author:	Timothy A. Yap, MBBS, PhD, FRCP Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and Investigator in the ACESOT-1051 study
Session:	Plenary Session (Oral Presentation)
Date and Time:	Friday, November 20, 2026, 3:00 PM - 3:10 PM CET
Location:	Room 111 + 112, CCIB, Barcelona.

For more information on the ACESOT-1051 trial, refer to ClinicalTrials.gov NCT06260514.

About Aprea Therapeutics

Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from our clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Media Contact:

Sean Naughton Ph.D.
Russo Partners, LLC
sean.naughton@russopartnersllc.com
(858) 717-2310